List of Excipients in Branded Drug CLOCORTOLONE PIVALATE CREAM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	CLOCORTOLONE PIVALATE CREAM	clocortolone pivalate	66993-947	CARBOMER HOMOPOLYMER TYPE B
Prasco Laboratories	CLOCORTOLONE PIVALATE CREAM	clocortolone pivalate	66993-947	EDETATE DISODIUM
Prasco Laboratories	CLOCORTOLONE PIVALATE CREAM	clocortolone pivalate	66993-947	METHYLPARABEN

Clocortolone Pivalate Cream Excipient Strategy and Commercial Opportunities

Last updated: August 18, 2026

Clocortolone pivalate cream 0.1% is a mature topical corticosteroid opportunity with limited active-ingredient differentiation. Commercial value is concentrated in excipient selection, semisolid equivalence, product feel, packaging, supply reliability, and channel positioning. The primary U.S. reference product is Cloderm cream 0.1%, approved under NDA 018632. Generic development generally follows the ANDA pathway, with the principal technical challenge being demonstration of pharmaceutical and therapeutic equivalence for a complex topical cream. [1][2]

What is clocortolone pivalate cream?

Clocortolone pivalate is a synthetic corticosteroid used for inflammatory and pruritic corticosteroid-responsive dermatoses. The marketed cream strength is 0.1% w/w. It is a small-molecule topical product, so biosimilar regulation does not apply.

The commercial product is a prescription dermatology cream intended for application to affected skin. The formulation must deliver:

• Uniform clocortolone pivalate distribution
• Consistent dose per unit surface area
• Adequate drug release from the cream base
• Acceptable spreadability and skin feel
• Physical and chemical stability
• Microbiological quality throughout shelf life
• Comparable clinical performance to the reference product

Topical creams are more difficult to copy than conventional immediate-release tablets because the vehicle can influence drug release, skin partitioning, evaporation, residue, and patient adherence.

What excipients are used in clocortolone pivalate cream?

The U.S. Cloderm cream label identifies a conventional oil-in-water cream system containing fatty alcohols, emulsifiers, humectants, emollients, buffering components, and purified water. The listed inactive ingredients include cetostearyl alcohol, cetyl alcohol, isopropyl myristate, polyethylene glycol 100 stearate, propylene glycol, purified water, sodium citrate, stearyl alcohol, and sorbitan monostearate. [1]

Excipient	Primary formulation function	Commercial relevance
Cetostearyl alcohol	Consistency agent, co-emulsifier, emollient	Controls viscosity, spreadability, and sensory profile
Cetyl alcohol	Fatty alcohol, emollient, thickener	Supports cream structure and skin feel
Stearyl alcohol	Thickener and emollient	Influences body, yield stress, and residue
Isopropyl myristate	Emollient and penetration-supporting vehicle	Affects glide, absorption, and greasiness
PEG-100 stearate	Nonionic emulsifier	Supports oil-in-water emulsion stability
Sorbitan monostearate	Co-emulsifier	Contributes to interfacial stability
Propylene glycol	Humectant and solvent	Supports hydration and drug wetting or solubilization
Sodium citrate	Buffering and pH control	Helps maintain pH during storage
Purified water	Continuous phase	Determines emulsion structure and microbial-control burden

The excipient list indicates a conventional cream rather than an anhydrous ointment, gel, foam, lotion, or hydroalcoholic solution. A generic applicant can use the same excipients, different suppliers, or a different composition, but the finished product must meet the relevant equivalence and performance requirements.

How should the excipient strategy be designed?

The lowest-risk strategy is a close qualitative and quantitative replication of the reference vehicle. A more differentiated strategy can improve sensory performance, manufacturing robustness, or packaging, but every formulation change increases development and regulatory risk.

Base architecture

The formulation should begin with an oil-in-water emulsion using:

1. A fatty-alcohol structural network
2. A nonionic emulsifier system
3. A moderate-humectancy solvent phase
4. A low-irritancy emollient phase
5. A controlled aqueous phase
6. A pH-adjustment and buffering system

This architecture is commercially attractive because it is familiar to dermatologists, compatible with tube packaging, and easier to manufacture at scale than a highly specialized delivery system.

Drug solubilization and dispersion

Clocortolone pivalate is a corticosteroid ester with limited water solubility. The formulation must control whether the drug is dissolved, partially dissolved, or suspended in the internal phase.

Key development variables include:

• Particle-size distribution
• Drug wetting
• Solvent concentration
• Crystallization tendency
• Drug distribution between oil and aqueous phases
• Impact of homogenization on particle morphology
• Release rate from the vehicle

A formulation that dissolves more drug is not automatically equivalent. Excessive apparent solubilization can alter thermodynamic activity and skin delivery. Conversely, uncontrolled crystallization can create dose nonuniformity and slow release.

Rheology and spreadability

Cream performance depends on more than nominal viscosity. Relevant parameters include:

• Yield stress
• Shear-thinning behavior
• Recovery after shear
• Extrusion force
• Spreadability
• Adhesion to skin
• Residue after rubbing

A product that is too stiff can reduce adherence and create tube-use complaints. A product that is too fluid can separate, leak, or deliver inconsistent doses. The target should be a stable, shear-thinning cream that spreads easily under finger pressure and recovers structure after application.

pH and skin tolerability

The formulation pH should support drug stability, emulsion integrity, preservative performance where applicable, and skin tolerability. Sodium citrate in the reference formulation indicates a controlled pH environment. The developer should avoid unnecessary pH excursions because they can affect:

• Emulsion droplet size
• Excipient degradation
• Drug hydrolysis
• Preservative effectiveness
• Skin irritation
• Packaging compatibility

Preservative strategy

A multidose aqueous cream requires a microbiological control strategy. The reference formulation’s publicly listed excipient profile does not identify a conventional named antimicrobial preservative such as parabens, phenoxyethanol, or benzyl alcohol. This creates a potentially valuable development question: whether microbiological control depends on the formulation environment, manufacturing controls, packaging, or a combination of factors.

A new product can pursue three routes:

Strategy	Benefits	Risks
Closely replicate reference preservation approach	Lower regulatory and equivalence risk	Less differentiation
Add a conventional preservative	Greater microbiological margin	Potential irritation, sensitization, and altered skin delivery
Use air-restrictive or unit-dose packaging	Reduced in-use contamination exposure	Higher packaging cost and patient-use complexity

A preservative-free or low-preservative cream could support premium positioning, but it requires strong in-use microbiological data and packaging validation. The commercial benefit is greatest for sensitive-skin and chronic-use segments, although clocortolone pivalate is generally used for time-limited treatment rather than indefinite maintenance.

What formulation patents protect clocortolone pivalate cream?

The principal commercial barrier is unlikely to be an unexpired composition-of-matter patent for clocortolone pivalate. The product is a mature corticosteroid formulation, and generic products have entered the U.S. market.

Potential intellectual-property areas include:

• Cream composition
• Drug-particle engineering
• Emulsion-processing conditions
• Preservative-free packaging
• Metered-dose delivery
• Treatment of specific dermatoses
• Combination products
• Stability-improving excipient systems
• Manufacturing methods

A developer should separate three patent categories:

Patent category	Relevance to clocortolone pivalate cream
Active-ingredient patent	Usually limited for a mature corticosteroid
Formulation patent	May cover a specific cream base or release profile
Method-of-use patent	May cover a disease, dosing regimen, or patient subgroup

FDA Orange Book-listed patents are the key U.S. reference for ANDA certification. The Cloderm reference product is listed under NDA 018632. [2] A product-specific freedom-to-operate review must also cover non-Orange Book patents, pending applications, packaging claims, and patents owned by generic developers.

What is the Orange Book status of clocortolone pivalate cream?

The regulatory reference product is Cloderm cream 0.1%, associated with NDA 018632 in FDA product records. The product is a small-molecule prescription topical and is eligible for conventional generic competition through an ANDA, subject to FDA requirements. [1][2]

The relevant regulatory issues are:

• Reference-listed-drug identification
• Patent and exclusivity certifications
• Product-specific labeling
• Pharmaceutical equivalence
• In vitro release performance
• Comparative characterization of the topical product
• Manufacturing-site compliance
• Stability and microbiological controls

FDA’s topical-product guidance recognizes that semisolid products require a broader characterization package than simple dosage forms. Applicants may need comparative data on composition, structure, rheology, particle size, globule size, viscosity, pH, metamorphosis, and in vitro release, depending on the product and agency requirements. [3]

When does clocortolone pivalate cream lose exclusivity?

Clocortolone pivalate cream is already a mature generic market. The key commercial question is therefore not the future loss of exclusivity for Cloderm but the durability of generic margins and the opportunity to improve the vehicle.

Exclusivity issue	Commercial assessment
New chemical entity exclusivity	Not commercially relevant to this mature product
Composition-of-matter patent	Expected to be expired or noncontrolling for current generic entry
Original product exclusivity	Historical rather than a current market barrier
Formulation patents	Must be reviewed individually
Method-of-use patents	May affect labeling or litigation strategy
Generic entry	Already commercially feasible
Biosimilar risk	None; the product is not a biologic

The market is therefore exposed to price competition, contract-manufacturer economics, pharmacy substitution, and payer formulary decisions.

How many patents cover clocortolone pivalate cream?

A single reliable patent count cannot be inferred from the drug name alone. Patent scope depends on jurisdiction, legal status, continuation practice, claim construction, and whether the search includes expired patents, abandoned applications, formulation patents, and use patents.

For U.S. generic planning, the relevant search set includes:

• Orange Book entries associated with NDA 018632
• U.S. patents naming clocortolone pivalate
• Patents covering corticosteroid cream vehicles
• Delivery and packaging patents
• Method-of-use claims for inflammatory skin disease
• Patent families assigned to the reference-product owner and generic manufacturers

The practical conclusion is that patent risk is likely to be lower than formulation-development risk. A weak patent position does not guarantee a profitable product if the ANDA formulation fails comparative performance testing or cannot achieve competitive manufacturing cost.

What generic entry risks exist?

Bioequivalence risk

Topical cream equivalence can fail because of differences in drug release, microstructure, or skin delivery. A formulation may match the inactive-ingredient list yet differ materially in:

• Droplet-size distribution
• Drug crystallinity
• Polymorphic form
• Viscosity under shear
• Phase behavior
• Water activity
• Drug release rate
• Evaporation profile

Manufacturing risk

The formulation is sensitive to process parameters such as:

• Heating and cooling curves
• Order of phase addition
• Homogenization energy
• Mixing time
• Bulk hold time
• Filling temperature
• Deaeration
• Shear exposure during transfer

These parameters should be treated as critical process variables rather than ordinary manufacturing settings.

Stability risk

Stability programs should evaluate:

• Assay and impurities
• Physical separation
• Viscosity drift
• pH
• Particle or crystal growth
• Tube compatibility
• Net-content recovery
• Microbial quality
• Repeated opening and closing
• Elevated-temperature excursions

Supply-chain risk

Fatty alcohols, PEG-based emulsifiers, specialty emollients, and pharmaceutical-grade solvents can create supplier concentration risk. Dual sourcing is commercially valuable, but supplier changes can alter impurity profiles, particle structure, odor, color, and rheology.

What commercial opportunities exist for clocortolone pivalate cream?

Low-cost generic cream

The largest opportunity is a reliable, low-cost generic with a formulation close to the reference product. The target customer is the pharmacy and payer channel, where substitution and reimbursement dominate prescribing decisions.

Premium sensory formulation

A differentiated cream can compete on:

• Faster rub-in
• Lower greasiness
• Reduced whitening
• Lower tack
• Improved spreadability
• Better washability
• Consistent extrusion force

These claims must be supported by appropriate product characterization and cannot imply superior clinical efficacy without evidence.

Sensitive-skin positioning

A formulation with reduced fragrance risk, a conservative excipient profile, and minimized sensitization concerns could target patients who discontinue topical products because of irritation or poor cosmetic acceptability.

Packaging innovation

Potential formats include:

• Aluminum tubes
• Laminated tubes
• Airless pumps
• Metered-dose dispensers
• Unit-dose sachets

Tubes are usually the lowest-cost option. Airless systems may support a preservative-reduction strategy, but they increase component cost, filling complexity, and device-performance requirements.

Contract manufacturing and private label

Because the active ingredient is mature and the product is relatively simple compared with advanced dermatology delivery systems, contract development and private-label supply can be commercially attractive. The differentiator is likely to be regulatory execution, batch consistency, and cost of goods rather than brand discovery.

How does clocortolone pivalate cream compare with competing topical corticosteroids?

Product class	Relative commercial position
Hydrocortisone creams	Lower potency, broad OTC and prescription competition
Desonide products	Low-potency prescription alternative
Triamcinolone acetonide creams	Broad generic availability and strong price competition
Betamethasone products	Higher-potency alternatives with different safety positioning
Clocortolone pivalate 0.1%	Mid-potency prescription product with a mature but narrower market

Clocortolone pivalate cream competes through potency, physician familiarity, vehicle acceptability, and payer access. It does not have the market exclusivity or specialty-pharmacy economics associated with newer nonsteroidal dermatology products.

What patent litigation affects clocortolone pivalate cream?

No major active litigation conclusion should be drawn solely from the FDA label or Orange Book listing. For a current generic launch, the relevant legal work is an ANDA patent-certification review, followed by a search of federal district court and appellate records for Paragraph IV complaints, settlements, and launch restrictions.

The expected litigation exposure is lower than for a recently approved branded dermatology product because clocortolone pivalate cream is mature and generic competition is established. The principal legal risks are product-specific formulation patents, method-of-use claims, and disputes over non-Orange Book intellectual property.

What revenue exposure does the reference product have?

Public FDA product records establish regulatory status but do not provide a complete, current product-level revenue series. Commercial exposure is likely concentrated in prescription dermatology channels and is constrained by:

• Generic substitution
• Payer formulary controls
• Low-to-moderate unit pricing
• Competition from other topical corticosteroids
• Limited differentiation in a conventional cream format

A launch model should use prescription volume, average realized price, payer mix, wholesaler discounts, gross-to-net deductions, and generic-share assumptions. The product is better suited to a portfolio strategy than to a standalone high-growth investment thesis.

Key Takeaways

• Clocortolone pivalate cream 0.1% is a mature prescription topical corticosteroid opportunity.
• Cloderm cream 0.1%, NDA 018632, is the principal U.S. reference product. [1][2]
• The core excipient platform uses fatty alcohols, nonionic emulsifiers, isopropyl myristate, propylene glycol, sodium citrate, and purified water.
• The highest-value formulation work concerns microstructure, drug release, rheology, preservation, and patient sensory experience.
• Generic entry is technically feasible but requires careful control of Q1, Q2, Q3, in vitro release, stability, and manufacturing parameters.
• Biosimilar competition is irrelevant because clocortolone pivalate is a small molecule.
• Commercial opportunities include low-cost generic supply, premium sensory positioning, sensitive-skin formulations, preservative-reduction strategies, and private-label manufacturing.
• Patent risk is likely lower than formulation and execution risk, but Orange Book and broader freedom-to-operate reviews remain central to launch planning.
• The most defensible product strategy is a reference-aligned cream with measurable improvements in spreadability, residue, packaging performance, or manufacturing cost.

FAQs

Is clocortolone pivalate cream a biologic?

No. Clocortolone pivalate is a small-molecule synthetic corticosteroid. Biosimilar approval and biologic interchangeability rules do not apply.

Can a generic use different excipients from Cloderm cream?

Yes. A generic may use a different inactive-ingredient composition if it satisfies FDA requirements for pharmaceutical equivalence, product quality, safety, labeling, and therapeutic equivalence.

Is a preservative-free clocortolone pivalate cream commercially viable?

It can be viable if the formulation and packaging maintain microbiological quality during storage and patient use. The concept is more commercially differentiated than a conventional generic but carries higher development and packaging risk.

What is the most important quality attribute for this cream?

No single attribute controls performance. The highest-risk group includes drug distribution, particle or crystal state, rheology, globule size, viscosity, pH, physical stability, and in vitro drug release.

Is clocortolone pivalate cream suitable for a 505(b)(2) product?

A 505(b)(2) strategy could be considered for a materially different dosage form, delivery system, or formulation with supporting clinical or pharmacokinetic justification. A conventional cream intended to copy the reference product is generally better aligned with the ANDA pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Cloderm (clocortolone pivalate) cream, 0.1% prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Draft guidance for industry. FDA.

4. U.S. Food and Drug Administration. (2016). ANDAs for certain highly purified synthetic peptides: Guidance for industry. FDA.